SciClone Announces Appointment of Simon Li to Its Board of

SciClone Announces Appointment of Simon Li to Its Board of Directors 
FOSTER CITY, CA -- (Marketwire) -- 01/14/13 --  SciClone
Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced the appointment
of Simon Li to its board of directors. Mr. Li is an accomplished and
respected leader in the pharmaceutical and medical device industries
in China and Asia, and brings to SciClone's board more than 30 years
of experience in executive management, corporate strategy, business,
financial and commercial operations, regulatory compliance, medical
affairs and healthcare policy in multinational companies. 
"Simon joins SciClone's board at an important and exciting time in
our evolution as a leading US-based specialty pharmaceutical company
focused on the China market, as we continue to put strategies in
place to build revenue and profitability, strengthen and streamline
our organization, increase the profitability of our product promotion
business and seek new product in-licensing opportunities," said
Friedhelm Blobel, Ph.D., President and Chief Executive Officer.
"Simon's international experience and perspective, combined with his
knowledge of emerging markets and success in building profitable
companies and managing complex operations, will be of significant
value to SciClone as we work to strengthen our position within the
top echelon of multinational pharma companies in China. The
management team and board of directors join me in welcoming him to
the SciClone team." 
Most recently, Mr. Li served as the Global Officer and Member of the
Executive Committee of Medtronic, a global medical technology
company, and also held the positions of President, Greater China and
Chairman of the Board, Medtronic-Weigao JV. Prior to Medtronic, Mr.
Li was the International Vice President, North Asia / New Business
Development, Asia Pacific / Strategic Medical Affairs, Asia Pacific
with Johnson & Johnson Medical, China. Earlier in his career with
J&J, he held the positions of International Vice President, North
Asia, Managing Director, China and Hong Kong, and Managing Director,
China. Prior to J&J, Mr. Li was President and Chief Operating Officer
of the ConvaTec business with Bristol-Myers Squibb in Hong Kong. He
also served as General Manager of the pharmaceutical distributor Y.C.
Woo & Co., Ltd. in Hong Kong. Mr. Li's current non-executive
activities include serving on the board of directors of Shandong
Weigao Group Medical Polymer, and he has received several industry
honors. He earned a Bachelor of Arts degree in social sciences from
the University of Hong Kong, an M.B.A. degree from Henley Management,
and an advanced E.M.B.A. from Harvard Business School. He is fluent
in English, Mandarin and Cantonese, and is based in Shanghai. 
About SciClone  
SciClone Pharmaceuticals is a US-based, China-focused specialty
pharmaceutical company with a product portfolio of therapies for
oncology, infectious diseases and cardiovascular, urological,
respiratory, and central nervous system disorders. SciClone's
ZADAXIN(R) (thymalfasin) is approved in over 30 countries and may be
used for the treatment of hepatitis B (HBV), hepatitis C (HCV) and
certain cancers, and as a vaccine adjuvant, according to the local
regulatory approvals. Besides ZADAXIN, SciClone markets about 14
mostly partnered products in China, including Depakine(R), the most
widely prescribed broad-spectrum anti-convulsant in China;
Tritace(R), an ACE inhibitor for the treatment of hypertension;
Stilnox(R), a fast-acting hypnotic for the short-term treatment of
insomnia (marketed as Ambien(R) in the US); and Aggrastat(R), a
recently-launched interventional cardiology product. SciClone is also
pursuing the registration of several other therapeutic products in
China. SciClone is headquartered in Foster City, California. For
additional information, please visit www.sciclone.com.  
Forward-Looking Statements  
This press release contains forward-looking statements regarding
expected financial results and expectations. Readers are urged to
consider statements that include the words "may," "will," "would,"
"could," "should," "might," "believes," "estimates," "projects,"
"potential," "expects," "plans," "anticipates," "intends,"
"continues," "forecast," "designed," "goal," "unaudited,"
"approximately" or the negative of those words or other comparable
words to be uncertain and forward-looking. These statements are
subject to risks and uncertainties that are difficult to predict and
actual outcomes may differ materially. These include risks and
uncertainties relating to: changes in results that may occur in
completing the close of SciClone's consolidated financial statements
for fiscal year 2012 and completing the audit of SciClone's
consolidated financial statements for fiscal year 2012; the course,
cost and outcome of regulatory matters; the Company's ability to
execute on its goals in China and on its objectives for revenue in
fiscal 2013; the challenges presented by integrating an acquired
business into existing operations; the variability in earnings on a
GAAP basis that may result from non-cash charges related to the
NovaMed acquisition; the dependence on third-party license, promotion
or distribution agreements including the need to renew such
agreements; operating an international business; the clinical trial
process, including the regulatory approval and the process of
initiating trials at, and enrolling patients at, clinical sites; the
effect of changes in its practices and policies related to the
Company's compliance programs and SciClone's ability to attract and
retain key personnel. SciClone cannot predict the timing or outcome
of the SEC and DOJ investigations, or of the level of its efforts
required to cooperate with those investigations, however the Company
has incurred substantial expenses in connection with the
investigations and related litigation and expects to incur additional
expense and the investigations could result in fines and further
changes in its internal control or other remediation measures that
could adversely affect its business. Please also refer to other risks
and uncertainties described in SciClone's filings with the SEC. All
forward-looking statements are based on information currently
available to SciClone and SciClone assumes no obligation to update
any such forward-looking statements. 
Ambien, Depakine, Stilnox and Tritace are registered trademarks of
Sanofi and/or its affiliates. 
Aggrastat is a registered trademark of Medicure International Inc. in
the United States, and Iroko Cardio LLC in numerous other countries. 
SciClone, SciClone Pharmaceuticals, the SciClone Pharmaceuticals
design, the SciClone logo and ZADAXIN are registered trademarks of
SciClone Pharmaceuticals, Inc. in the United States and numerous
other countries. 
Corporate Contacts 
Gary Titus
Chief Financial Officer
650.358.3456
gtitus@sciclone.com 
Jane Green 
Investors/Media
650.358.1447
jgreen@sciclone.com